Single-Dose Rexinoid Rapidly and Specifically Suppresses Serum Thyrotropin in Normal Subjects

University of Houston, Houston, Texas, United States
Journal of Clinical Endocrinology & Metabolism (Impact Factor: 6.21). 01/2007; 92(1):124-30. DOI: 10.1210/jc.2006-0696
Source: PubMed


Retinoid X receptor agonists (rexinoids) have demonstrated benefit in patients with certain malignancies but appear to cause central hypothyroidism in some patients with advanced cancer. The influence of rexinoids on thyroid function in healthy subjects is not clear.
The objective of this study was to determine the effect of a single dose of bexarotene on levels of TSH, T4, and T3 in healthy subjects.
This study was a randomized, double-blind, placebo-controlled, crossover trial.
This study was conducted at the General Clinical Research Center (University of Colorado Health Sciences Center, Aurora, CO).
Six healthy adults (>18 yr old) were studied.
Single-dose rexinoid (bexarotene, 400 mg/m2) or placebo, with TSH measurements at 0, 1, 2, 4, 8, 12, 24, and 48 h, were used.
The main outcome was the serum TSH level at 24 h.
Single-dose bexarotene suppressed serum TSH (P < 0.001) over time. Compared with placebo, levels of TSH were significantly lower by 12 h (P = 0.043); the nadir of 0.32 +/- 0.02 mU/liter (P < 0.001) was seen at 24 h. Free T4 index and free T3 index were also significantly lower than placebo over time (48 h) (P = 0.029; P = 0.004, respectively). Serum prolactin, cortisol, and triglycerides were not affected (P > 0.05 for all). There was no significant effect of single-dose bexarotene on rT3 or T3/rT3 ratio at 24 h.
A single dose of a rexinoid can rapidly and specifically suppress serum TSH levels in healthy subjects. These data provide insight into the mechanisms by which rexinoids cause central hypothyroidism and potential ways this effect can be used for treatment of disorders such as thyroid hormone resistance and TSH-secreting pituitary tumors.

Full-text preview

Available from:
  • [Show abstract] [Hide abstract]
    ABSTRACT: Understanding and identifying medication-induced changes in thyroid function tests is crucial to avoid unnecessary investigations and treatment. This chapter discusses the effects of medications on the secretion, transport, metabolism, and absorption of thyroid hormones, both endogenous and exogenous (Fig. 13.1).
    No preview · Article · Sep 1973 · Ugeskrift for laeger
  • [Show abstract] [Hide abstract]
    ABSTRACT: Therapy with the retinoid X receptor agonist bexarotene is associated with hypothyroidism caused by decreased pituitary TSH secretion. To evaluate the effects of bexarotene on peripheral thyroid hormone metabolism, we performed a study in athyreotic subjects on a fixed substitution dose with L-T4. The design was an open prospective 6-wk intervention study. Ten athyreotic patients with pulmonary metastases of differentiated thyroid carcinoma received 6-wk redifferentiation treatment with 300 mg bexarotene/d. L-T4 doses were kept stable. Before and in the sixth week of therapy, serum levels of total T4, free T4 (FT4), T3, reverse T3 (rT3), and TSH were measured. To study nondeiodinase-mediated thyroid hormone degradation, serum levels of T4 sulfate (T4S) were measured. Recombinant human TSH was administered before and in the sixth week of bexarotene therapy. Bexarotene induced profound decreases in total T4 (56% of baseline), FT4 (47%), T3 (69%), rT3 (51%), and T4S (70%) in all patients, whereas TSH levels were not affected. The T3/rT3 ratio increased by 43%, and the T4S/FT4 ratio increased by 48%. Serum TSH levels before and after recombinant human TSH were unaffected by bexarotene. In the present study, we demonstrate that increased peripheral degradation of thyroid hormones by a nondeiodinase-mediated pathway contributes to bexarotene induced-hypothyroidism.
    No preview · Article · Aug 2007 · Journal of Clinical Endocrinology & Metabolism

  • No preview · Article · Jan 2008 · Nature Clinical Practice Oncology
Show more